admin – Page 5019 – Get News Story

Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

In October 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer. The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
In October 2024:- Merck Sharp & Dohme LLC- A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98). This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
In October 2024:- Mirati Therapeutics Inc.- A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation. CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
In October 2024- Novartis Pharmaceuticals- The Drugs Controller General of India (DCGI) has granted approval for Rahika® (Capmatinib) film-coated tablet 150 and 200 mg for the treatment of adult patients with advanced/metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping mutation with condition to perform a Phase IV clinical trial in Indian patients. As recommended by DCGI, this Phase IV study has been planned to evaluate the safety and efficacy of capmatinib in treatment of adult Indian patients with advanced/metastatic NSCLC whose tumors have a MET exon 14 skipping mutation positive advanced NSCLC in any line of therapy.
In October 2024:- Boehringer Ingelheim- This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.
In October 2024:- AstraZeneca- This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer.
DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

Stay informed about the cutting-edge advancements in Small Cell Lung Cancer treatments. Download for updates and be a part of the revolution in care @ Small Cell Lung Cancer Clinical Trials Assessment

Small Cell Lung Cancer Emerging Drugs Profile

AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

Learn more about Small Cell Lung Cancer Drugs opportunities in our groundbreaking Psoriasis Research and development projects @ Small Cell Lung Cancer Unmet Needs

Small Cell Lung Cancer Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Discover the latest advancements in Small Cell Lung Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Small Cell Lung Cancer Pipeline Report

Coverage- Global
Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Small Cell Lung Cancer Pipeline on our website @ Small Cell Lung Cancer Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer Collaboration Deals
Late Stage Products (Phase III)
Pembrolizumab: Merck & Co
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Dostarlimab: GlaxoSmithKline
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AMG 757: Amgen
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
S 055746: Vernalis
Drug profiles in the detailed report…..
Inactive Products
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Oakio Launches the WPC Proshield Beam for Winter-Ready Outdoor Structures

Oakio, a leading manufacturer of Wood-Plastic Composite (WPC) products, presents the WPC Proshield Beam, engineered to enhance the durability and functionality of outdoor structures during the winter months. With its superior weather resistance and low maintenance, the Proshield Beam is the perfect solution for homeowners and builders looking to create robust, winter-ready designs.

Engineered for Winter Durability

The WPC Proshield Beam is crafted from a premium blend of 55% wood fiber, 35% plastic resin, and 10% additives, resulting in a composite that stands up to harsh winter conditions. Unlike traditional wood beams that can warp, crack, or rot when exposed to moisture and freezing temperatures, the Proshield Beam is specifically designed to resist these issues. Its robust structure maintains its integrity, ensuring that outdoor structures remain safe and reliable throughout the winter season.

Low Maintenance for Peace of Mind

One of the standout features of the WPC Proshield Beam is its low-maintenance nature. Traditional wood beams often require regular staining, sealing, or painting to protect against winter weather. In contrast, the Proshield Beam retains its color and structural integrity without the need for frequent upkeep. This makes it a smart choice for busy homeowners or contractors looking to minimize maintenance while maximizing performance.

Versatile Applications for Outdoor Living

The Proshield Beam is perfect for a variety of outdoor applications, making it an ideal choice for winter projects. Whether used in pergolas, gazebos, or covered decks, this beam offers the strength and stability needed to support winter weather elements. Its design allows for seamless integration into various architectural styles, providing both aesthetic appeal and functionality.

About Oakio

Oakio is a leading manufacturer in the Wood-Plastic Composite (WPC) industry, dedicated to providing eco-friendly and sustainable solutions for outdoor living. From decking to beams and beyond, Oakio’s products are designed to enhance outdoor spaces with long-lasting durability and low maintenance. The WPC Proshield Beam exemplifies Oakio’s commitment to quality and innovation, making it the ideal choice for winter-ready outdoor structures.

For more information about the Proshield Beam and other Oakio products, visit www.oakio.com.

Media Contact
Company Name: Oakio
Contact Person: Juno Zhong
Email: Send Email
Country: China
Website: https://www.oakio.com/

Botanic Wellness Introduces The Hempcrete Initiative

“Our initiative embodies the essence of Botanic Wellness – a blend of innovative, eco-friendly solutions with practical applications,” Jason Oran

Botanic Wellness introduces The Hempcrete Initiative which aims to create affordable housing options in Suriname through its eco-friendly hempcrete. Leveraging high-quality hemp plants and local building resources, The Hempcrete Initiative combines economic development and eco-friendly construction practices to ultimately reduce the carbon footprint needed to build new homes while simultaneously providing much-needed affordable housing to the people of Suriname.

MELBOURNE, LONDON, PHOENIX – In a significant stride towards environmentally friendly building practices, Botanic Wellness, a leader in hemp-based innovations, is excited to announce its latest venture: The Hempcrete Initiative. This initiative seeks to adopt and adapt the benefits of hempcrete, an eco-friendly alternative to traditional concrete, fundamentally reshaping the construction landscape.

Currently, Botanic Wellness is concentrating its efforts on hemp cultivation, nearing its target of 20 hectares dedicated to supplying the raw materials required for the Hempcrete Initiative in Suriname. This groundbreaking project aims to build a community of twelve houses using sustainable hempcrete material.Hempcrete, made from the wood-like core of the hemp plant combined with a lime-based binder, has been gaining global recognition for its environmentally friendly properties.

Botanic Wellness’s Initiative aims to bring this proven technology to Suriname, focusing on local sourcing and application to promote environmental conservation and sustainable development in construction, replacing almost all imported materials like Portland cement with local alternatives wherever possible.

This approach not only benefits the environment by reducing carbon footprint but also supports the local economy. Sourcing materials locally and engaging resident workers and companies in the construction process underscores Botanic Wellness’ broader commitment to Suriname’s holistic development. Jason Oran, Head of Farming at Botanic Wellness, leads The Hempcrete Initiative in partnership with Roots Agriculture. Oran shares Botanic Wellness’ vision, stating, “Our role in The Hempcrete Initiative is not about reinventing but about innovating on implementation. We are focusing on the scalable application of hempcrete, from its use in insulation to creating entire hempcrete-based structures tailored to specific building codes and climates.”

In Suriname, the project aims to demonstrate hempcrete’s versatility through a pilot construction project, which includes building affordable housing using exclusively hempcrete materials. This endeavor is not only a testbed for the material’s real-world applications but also serves as an educational platform to advocate for sustainable building techniques within the region. The choice of affordable housing reflects Botanic Wellness’s commitment to fostering community engagement and economic development, highlighting the dual benefits of hempcrete in both construction and community enrichment. “Our initiative embodies the essence of Botanic Wellness – a blend of innovative, eco-friendly solutions with practical applications,” Oran adds. “While hempcrete itself is not new, our approach to its application, especially in the context of Suriname and the potential scalability of this model globally, is what sets us apart.”

The project represents a vital component of Botanic Wellness’s broader vision for environmental consciousness and innovation. Through the Hemp-Crete Initiative, Botanic Wellness is not just focusing on the environmental impacts of construction but is also laying the foundation for future projects that will further cement their commitment to green technology and truly eco-friendly business practices.

Now in the process of determining proof of concept in Suriname, Botanic Wellness has aspirations to eventually farm 100 hectares of land and expand the application of hempcrete to projects in Australia and other South American countries, positioning themselves as leaders in eco-friendly construction across multiple regions. Botanic Wellness Innovations = A Better World.

About Botanic Wellness

Botanic Wellness, established in 2019 and headquartered in Australia, has emerged as a leading global player in the rapidly growing and developing hemp industry. Through forward-looking, eco-friendly, hemp-based bioplastic, resins, etc., Botanic Wellness enables customers across markets to benefit from sustainable, high-quality hemp solutions. With international subsidiaries, including the US, UK, and Australian operations, the global company continues to grow with a diverse portfolio, charting the path forward in hemp-based biodegradable products; utilizing its vast network and cutting-edge farming and processing techniques, Botanic Wellness skillfully navigates the complexity of hemp production, ensuring the highest quality, and compliance with stringent guidelines. At the heart, Botanic Wellness strives to meet the ever-changing demands of the market through its commitment to integrity, service, and the environment.

For More Information on Botanic Wellness, please visit:

Botanic Wellness AU

Instagram

All products and services mentioned, created, and rendered by Botanic Wellness Ltd. are in compliance with the 2018 Farm Bill, as well as the Novel Foods Regulations.

Media Contact
Company Name: Botanic Wellness
Contact Person: Rhonda Peoples
Email: Send Email
Phone: (520) 245-6821
Address:2847 S Gilbert Road Suite 106-410 Gilbert, Arizona
City: Gilbert
State: Arizona
Country: United States
Website: http://www.botanicwellnessusa.com

Precision Fermentation Ingredients Market Report: Insights into Trends, Opportunities, and Competitive Landscape

“MarketsandMarkets™”

Precision Fermentation Ingredients Market by Ingredient (Whey & Casein Protein, Egg White, Collagen Protein, Heme Protein), Microbe (Yeast, Algae, Fungi, Bacteria) End User, Food & Beverage Application, and Region – Global Forecast to 2030

The global precision fermentation ingredients market is estimated to be valued at USD 2.8 billion in 2023 and is projected to reach USD 36.3 billion by 2030, achieving a CAGR of 44.0%. Key drivers of this growth include shifting consumer preferences towards veganism, increasing protein consumption, and rising investments in innovation. Significant advancements in genetic engineering have facilitated the sustainable and cost-effective reprogramming of microorganisms through precision fermentation, enabling the production of a diverse range of specialized food protein components.

Precision Fermentation Ingredients Market

This burgeoning industry presents lucrative opportunities for market participants. For example, in May 2023, Geltor launched CAVIANCE™, a vegan collagen polypeptide that provides exceptional skin rejuvenation benefits. This innovative product promotes six different types of collagen, possesses strong antioxidant properties, and supports wound healing. Additionally, MycoTechnology has initiated a groundbreaking partnership with the Oman Investment Authority (OIA) to develop mushroom-based protein using locally sourced dates, creating a new entity named Vital Foods Technologies LLC.

The precision fermentation ingredients market is characterized by strong competition, with the top five players—Geltor (US), Perfect Day, Inc. (US), The Every Co. (US), Impossible Foods Inc. (US), and Motif FoodWorks, Inc. (US)—holding between 25% and 50% of the market share.

Precision Fermentation Ingredients Market Overview

Precision fermentation is an advanced biotechnology process that uses microorganisms, such as bacteria, yeast, or fungi, to produce specific ingredients with high precision and efficiency. These ingredients are widely used in food, beverages, pharmaceuticals, and other industries. The market for precision fermentation ingredients encompasses various products, including proteins, enzymes, amino acids, and other bio-based compounds.

Key Drivers

Sustainable Production: Increasing demand for sustainable and environmentally friendly production methods is driving the adoption of precision fermentation. This method reduces the need for animal agriculture, lowering greenhouse gas emissions and resource consumption.

Health and Wellness Trends: The rising interest in health and wellness, particularly among consumers seeking plant-based and alternative protein sources, is boosting the demand for precision fermentation ingredients.

Technological Advancements: Innovations in biotechnology and fermentation technologies have enhanced the efficiency, scalability, and cost-effectiveness of precision fermentation processes.

Regulatory Support: Supportive government policies and regulations promoting sustainable food production methods are fostering growth in the precision fermentation ingredients market.

Challenges

High Initial Costs: The high upfront costs associated with setting up precision fermentation facilities can be a barrier for new entrants.

Regulatory Hurdles: Navigating the complex regulatory landscape for food ingredients can be challenging, particularly for new and innovative products.

Competition: The market is competitive, with several players working on similar technologies, which may lead to price wars and reduced margins.

Precision Fermentation Ingredients Market Trends

Here are some key trends shaping the precision fermentation ingredients market:

Growing Demand for Sustainable Ingredients: With increasing awareness about environmental sustainability and concerns over traditional agricultural practices, there’s a rising demand for sustainable alternatives. Precision fermentation offers a promising solution by providing ingredients that are produced with minimal environmental impact, such as reduced land and water usage and lower greenhouse gas emissions.

Expansion in Food and Beverage Industry: The food and beverage industry is one of the primary sectors driving the adoption of precision fermentation ingredients. Companies are incorporating these ingredients into a wide range of products, including meat substitutes, dairy alternatives, flavors, and nutritional supplements. This trend is driven by consumer preferences for healthier, plant-based options and innovative flavors.

Technological Advancements: Advances in biotechnology, genetic engineering, and fermentation processes are driving the development of new and improved precision fermentation techniques. These advancements enable more efficient production processes, higher yields, and the customization of ingredients to meet specific requirements, such as taste, texture, and nutritional profile.

Investment and Collaboration: The precision fermentation industry has attracted significant investment from both traditional food and beverage companies and venture capital firms. Additionally, collaborations between startups, research institutions, and established players are becoming increasingly common. These partnerships facilitate knowledge sharing, access to resources, and the development of innovative products.

Regulatory Landscape: As precision fermentation ingredients gain traction in the market, regulatory frameworks governing their production, labeling, and safety are evolving. Regulatory agencies are working to establish clear guidelines to ensure the safety and quality of these ingredients while addressing consumer concerns and promoting transparency in labeling.

Diversification of Applications: Precision fermentation ingredients are finding applications beyond the food and beverage industry, including in pharmaceuticals, cosmetics, and animal feed. This diversification of applications opens up new opportunities for market growth and innovation as companies explore novel uses for these ingredients.

Consumer Awareness and Acceptance: Consumer awareness of precision fermentation and acceptance of products containing these ingredients are increasing. As more information becomes available about the benefits of precision fermentation, consumers are becoming more open to trying products made with these ingredients, further driving market demand.

What factors are driving the growth of the precision fermentation ingredients market in the Asia Pacific region?

The Asia Pacific precision fermentation ingredients market is primarily driven by rapid urbanization and shifting lifestyles, which have created a growing demand for specialized products like alternative proteins and sustainable ingredients—areas where precision fermentation excels. The region’s commitment to technological advancements and innovation supports the cutting-edge nature of precision fermentation ingredients, creating a robust environment for research and development. Furthermore, consumers across the region are not only curious about innovative products but are also eager to make purchases. Additionally, ongoing investments and expansions further propel the growth of the precision fermentation market in Asia Pacific.

Top Precision Fermentation Ingredients Companies

Key players operating in this market include Geltor (US), Perfect Day, Inc. (US), The Every Co. (US), Impossible Foods Inc. (US), Motif FoodWorks, INC. (US), Imagindairy Ltd. (Israel), Shiru, Inc. (US), Formo (Germany), Eden Brew (Australia), Change Foods (US), and New Culture (US).

Geltor is a prominent bio-design firm that pioneers in advanced designer proteins. Integrating fermentation, biology, and protein optimization, Geltor produces sustainable and efficient alternative proteins with enhanced functionality. Their 100% animal-free and GMO-free ingredients are globally scalable and cultivated sustainably. Leveraging microbes, the company employs a fermentation process to create products using plant-based and renewable resources. In 2023, Geltor introduced Nucoll and Caviance, novel products catering to haircare and skincare needs. This evolution signifies a transformative approach to beauty and wellness, harnessing biotechnology’s potential for creating effective and eco-friendly alternatives.

Impossible Foods is engaged in providing plant-based fish, dairy, and meat products. The company’s product portfolio includes various plant-based products such as burgers, sausages, chicken nuggets, pork, and meatballs. Impossible Foods includes soy leghemoglobin manufactured through precision fermentation into its plant-based burger to provide the end product with the desired meat-like texture and taste. The company has its manufacturing facility located in Oakland, CA, US. Additionally, the company has partnered with one of the foremost food processing companies in the US, OSI Group, which provides extra manufacturing space to produce the popular Impossible Sausage and Impossible Burger. As a globally recognized entity, Impossible Foods serves customers across multiple countries, including the United States, Australia, Canada, Hong Kong, Macau, New Zealand, Singapore, the United Arab Emirates, and the United Kingdom.

Precision Fermentation Ingredients Market Industry News

In May 2023, The EVERY Company and Alpha Foods officially entered into a Joint Development Agreement with the shared objective of bringing next-generation alt-meat products to the market. This collaboration aims to leverage EVERY’s trailblazing expertise in animal-free protein production and Alpha Foods’ renowned chef-crafted plant-based foods to accelerate advancements in taste and texture for non-animal products.

In March 2023, the partnership between The Hartman Group, Perfect Day, and Cargill enabled Perfect Day to gain valuable insights into consumer attitudes and preferences related to precision fermentation ingredients. This data has helped Perfect Day strengthen its position in the market, spearhead the Precision fermentation Alliance

In October 2022, Impossible Foods’ collaboration with Domino’s Australia, introducing Impossible™ Beef on their pizzas, strategically expands their market presence, boosts brand exposure, and appeals to environmentally conscious consumers.

Precision Fermentation Ingredients Market Segmentation:

By Microbe

Yeast

Algae

Fungi

Bacteria

By Ingredients

Whey & Casein Protein

Egg White

Collagen Protein

Heme Protein

Enzymes

Others

By End Use

Food & Beverages

Pharmaceutical

cosmetics & Others

By Food & Beverage Application

Meat & seafood

Dairy alternatives

Egg alternatives

Others

By Region

North America

Europe

Asia Pacific

South America

Middle East & Africa

Key Questions Addressed by the Precision Fermentation Ingredients Market Report:

What is the projected market value of the global precision fermentation ingredients market?

What is the estimated growth rate (CAGR) of the global precision fermentation ingredients market for the next five years?

Which are the major companies in the precision fermentation ingredients market?

What is the future growth potential of precision fermentation ingredients market?

What kind of information is provided in the competitive landscape section?

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/precision-fermentation-market-30824914.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Precision Fermentation Ingredients Market Report: Insights into Trends, Opportunities, and Competitive Landscape

Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Breast Cancer Pipeline Outlook

Key Takeaways from the Breast Cancer Pipeline Report

In October 2024:- Merck Sharp & Dohme LLC- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer. The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician’s Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
In October 2024:- Eli Lilly and Company- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
In October 2024- Novartis Pharmaceuticals- A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment, Including a Subset With Pharmacokinetic Analysis.
In October 2024:- Pfizer- The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.
DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment

Breast Cancer Emerging Drugs Profile

SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer.

HLX11: Shanghai Henlius Biotech

HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.

Praluzatamab ravtansine: CytomX Therapeutics

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

MCLA-128: Merus N.V.

MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.

DX126 262: Hangzhou DAC Biotech

DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Breast Cancer Drugs

Breast Cancer Companies

Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Breast Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Breast Cancer Market Drivers and Barriers

Scope of the Breast Cancer Pipeline Report

Coverage- Global
Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Breast Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
MCLA-128: Merus N.V.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DX126 262: Hangzhou DAC Biotech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ES2B C001: ExpreS2ion Biotechnologies
Drug profiles in the detailed report…..
Inactive Products
Breast Cancer Companies
Breast Cancer Products
Breast Cancer Unmet Needs
Breast Cancer Market Drivers and Barriers
Breast Cancer Future Perspectives and Conclusion
Breast Cancer Analyst Views
Breast Cancer Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Probiotics in Animal Feed Market Set to Reach New Heights: A Comprehensive Analysis of Trends and Innovations

“MarketsandMarkets™”

Probiotics in Animal Feed Market by Livestock (Poultry, Swine, Ruminants, Aquaculture, Pets), Source (Bacteria, Yeast, Fungi), Form (Dry, Liquid), Function (Nutrition, Gut Health, Immunity, Productivity), & Region – Global Forecast to 2028

The global probiotics in animal feed market was valued at approximately USD 4.2 billion in 2022. It is anticipated to grow to around USD 4.6 billion in 2023, with a projected compound annual growth rate (CAGR) of 9.1%, reaching an estimated USD 7.1 billion by 2028. The incorporation of probiotics in animal feed has been shown to significantly benefit livestock health by boosting immune function, enhancing digestive health, and improving growth performance and feed conversion ratios. Key factors driving the market include the prevalence of disease outbreaks, increasing pressure on feed productivity and conversion rates, and a rising demand for livestock-based food products. However, the high research and development costs associated with creating new probiotic strains present a challenge for market expansion.

The Asia Pacific region is expected to be one of the fastest-growing areas, as modernization in animal feed production creates substantial opportunities for feed additive manufacturers, fueling growth. Probiotics are extensively used in various livestock sectors, including ruminants, poultry, swine, aquaculture, and pets, to improve gut health, carcass yield, immunity, and overall productivity.

Probiotics in Animal Feed Market Trends

Here are some key trends shaping the probiotics in the animal feed market:

Growing Demand for Natural Feed Additives: There is an increasing preference for natural and organic ingredients in animal nutrition, driven by consumer awareness and regulatory pressures. Probiotics are seen as a safe and effective alternative to antibiotics and chemical additives.

Rising Livestock Production: The global demand for animal protein is increasing, leading to a rise in livestock production. Probiotics are increasingly being used to enhance animal health and growth rates, thereby supporting this demand.

Focus on Animal Health and Welfare: Animal welfare concerns are prompting farmers to seek alternatives to conventional feed additives. Probiotics improve gut health, immunity, and overall well-being, aligning with the trend towards more humane farming practices.

Technological Advancements: Innovations in probiotic formulations and delivery methods, such as encapsulation and microencapsulation, are enhancing the stability and efficacy of probiotics in animal feed. This is making probiotics more appealing to livestock producers.

Regulatory Support: Many governments are encouraging the use of probiotics in animal feed through supportive regulations and guidelines. This is fostering research and development in this area, leading to more widespread adoption.

Increasing Consumer Awareness: With the rise of health-conscious consumers, there is growing awareness about the benefits of probiotics, not just for humans but also for animals. This is driving demand for probiotic-enhanced animal products.

Diverse Applications: Probiotics are being applied across various livestock categories, including poultry, swine, ruminants, and aquaculture. This diversification is expanding the market reach and opportunities for growth.

Sustainability Trends: The shift towards sustainable farming practices is driving the demand for probiotics, as they can help reduce reliance on antibiotics and promote eco-friendly farming methods.

Rising Feed Productivity and Conversion Rate Challenges Boost Demand for Probiotics in Animal Feed.

The feed conversion rate (FCR) refers to the efficiency with which livestock convert feed into the desired outputs, such as meat or milk. With the rising demand for livestock products, the industry faces increasing pressure to supply high-value animal protein. This demand has led to a growth in livestock populations, which in turn has driven up the consumption of probiotics in animal feed. Probiotics enhance the nutritional value of feed by acting as bactericidal agents, improving gut health, and promoting growth, ultimately boosting livestock performance. As a result, feed containing probiotics improves the feed conversion rate, helping to meet market demands.

Incorporating probiotics into animal feed significantly supports livestock health and productivity by enhancing digestion and feed efficiency. The growing need for improved feed productivity and quicker feed conversion rates is thus driving the market for probiotics in animal feed.

Rising incidence of disease outbreaks is expected to drive market growth.

Unsafe and adulterated feed ingredients can weaken animal immunity, leading to reduced productivity and compromised quality of animal products. The rising incidence of disease outbreaks has prompted livestock farmers to seek higher-quality feed products with beneficial additives. Customers have consistently prioritized safety and quality, as disease outbreaks can disrupt the production, trade, and consumption of livestock products, including dairy, meat, eggs, and other by-products. Regions impacted by these outbreaks often face export bans for extended periods until they are fully quarantined and controlled.

Recently, the Asia Pacific region has seen outbreaks of the SARA-CoV-2 virus (2019), H5N1 influenza virus (2014), and foot-and-mouth disease (2011), all of which have adversely affected trade and resulted in significant losses for livestock producers, driven by heightened awareness of animal welfare issues. Additionally, concerns about animal health deterioration linked to pharmaceuticals in feed have led livestock farmers to increasingly demand more nutritious products. As a result, the demand for probiotic animal feed is expected to grow rapidly.

What factors contribute to Asia Pacific’s expected dominance in the market during the forecast period?

The study encompasses countries like China, India, Japan, Australia, New Zealand, and other nations in the Asia Pacific region. Several factors contribute to the strong demand in this market, including a growing population, increasing disposable incomes, and rapid urbanization. The rising demand for meat and animal products among the expanding population, coupled with greater affluence, has led to a surge in meat consumption. Consequently, this has driven intensified livestock production, heightening the need for improved animal health and performance.

In developing economies like India and China, the growth of the meat industry and the rising demand for high-quality meat products are key factors fueling the Asian market. Concerns about livestock diseases and infection outbreaks have further underscored the importance of animal health and wellness for ensuring consumer safety. Additionally, globalization and urbanization have shifted consumer preferences toward nutritious, high-quality food products, encouraging experimentation with diverse food choices. These trends are expected to persist in the coming years, propelling the demand for probiotics in the animal feed market.

Top Probiotics in Animal Feed Companies

The key players in this market include ADM (US), International Flavors & Fragrances Inc. (US), CHR. HANSEN HOLDING A/S (Denmark), Evonik Industries AG (Germany), Land O’Lakes (US), DSM (Netherlands), Ohly (Germany), Novozymes (Denmark), Alltech (US), Kemin Industries, Inc. (US), Provita Animal Health (UK), Orffa (Netherlands), Lesaffre (France), Lallemand Inc. (Canada). These players have adopted various growth strategies such as partnerships, agreements, collaborations, and new product launches to increase their global market presence.

ADM (US), ADM primarily produces food & feed ingredients. It is one of the key players in the agricultural processing and food ingredient sectors. The company is also involved in the trade, transport, storage, and processing of various grains and commodities. The company engages in the production, sale, and supply of specialty products, including emulsifiers, natural flavor ingredients, natural health and nutrition products, natural colors, flavor systems, proteins, polyols, soluble fiber, hydrocolloids, and other specialty food & feed ingredients. The company’s network spans across more than 190 countries around the world. The company has four business segments, namely Ag Services and Oilseeds, Carbohydrate Solutions, Nutrition, and Other Business. It provides probiotics through the Nutrition segment for animal consumption and other food applications. ADM’s manufacturing facilities are certified SEDEX, HACCP, by SGS North America, Organic by Ecocert ICO, and APHIS. In August 2018, ADM acquired Probiotics International Limited (PIL) (UK) that operates under its umbrella brand Protexin, which accounts for a deal of USD 235 million. It will be named ADM Protexin Limited, which produces research-based probiotics, including its Bio-Kult and Lepicol brands. Protexin also offers a variety of natural products and probiotic supplements for the veterinary, agriculture, and equine healthcare markets . This acquisition will help ADM in enhancing its product portfolio for probiotics in animal feed as it will offer supplements for equine livestock.

International Flavors & Fragrances Inc. (US), International Flavors & Fragrances Inc. (IFF) is one of the global multinational corporations that provide a range of products such as animal health solutions, extracts and flavorings, carob protein, cellulose gum, and cultures for food, among others. The company is active across various industries such as animal nutrition, antimicrobial fabric protection, biorefinery, brewing, dietary supplements, fabric & home care, food & beverage and hygiene, and odor control. The company operates through its major business segments: Nourish, Health and Biosciences, Scent, Pharma Solutions. It offers probiotics for animal feed under its Health & Biosciences Segment. Since its inception, the company has a strong focus on research and development and invests a significant amount in R&D activities every year. Through its numerous subsidiaries, IFF has significantly marked its presence in more than 200 countries. In February 2021, International Flavors & Fragrances Inc. merged with DuPont’s Nutrition & Biosciences business to deliver consumer-oriented products for food & beverage, personal care and health & wellness markets. This strategic initiative was undertaken to strengthen the product portfolios and R&D capabilities in probiotics ingredient and multiple other segments such as enzymes, culture, soy proteins, nutrition, scent among others.

Chr. Hansen Holding A/S (Denmark), is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. It is serving around its customers for almost 150 years to enable sustainable agriculture, better food and healthier living. It offers products and solutions through two segments namely Food Cultures & Enzymes and Health & Nutrition. It offers probiotics for animal feed derived from plants through Health & Nutrition segment. Chr. Hansen Holding A/S has a regional sales presence in all the world’s major markets, including North America, Latin America, Asia Pacific, Europe, Middle East, and Africa, giving the company a strong foothold in the global markets. In May 2021, company launched a product Bovacillus. The product is launched in the Argentinian market, which is a new solution to support dairy and beef cattle health & performance. This will enhance the company’s product portfolio for probiotics in animal feed and the customer reach in the region as well.

Probiotics in Animal Feed Market Segmentation:

This research report categorizes the probiotics in animal feed market, based on Livestock, Source, Form, Distribution Channel, Function, and Region.

By Livestock

Poultry

Swine

Ruminants

Aquaculture

Pets

Other Livestock

By Source

Bacteria

Yeast and Fungi

By Form

Dry

Liquid

By Distribution Channel

Direct Sales to Distributors

Direct Sales to Livestock Growers

Other Distribution Channels

By Function

Nutrition

Gut Health

Immunity

Productivity

By Region

North America

Europe

Asia Pacific

South America

Rest of the World (RoW)

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=85832335

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Probiotics in Animal Feed Market Set to Reach New Heights: A Comprehensive Analysis of Trends and Innovations

Bladder Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Bladder Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Bladder Cancer Research. Learn more about our innovative pipeline today! @ Bladder Cancer Pipeline Outlook

Key Takeaways from the Bladder Cancer Pipeline Report

In October 2024:- CG Oncology Inc.- A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT). Participants will be randomized 1:1 to cretostimogene grenadenorepvec after TURBT (Arm A) vs observation after TURBT (Arm B). Participants in Arm A will receive an induction course and then quarterly maintenance courses of cretostimogene through Month 13, if there is no disease recurrence.
In October 2024:- UNICANCER- An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer. This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to evaluate the efficacy of atezolizumab as measured by Event-Free survival.
In October 2024:- Merck Sharp & Dohme LLC- A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.
In October 2024:- Janssen Rsearch & Development LLC- A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy. The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
In October 2024:- NYU Langone Health- The investigators hypothesize that the addition of immune checkpoint inhibition with pembrolizumab, an anti-PD-1 inhibitor, to chemo-radiation therapy to the bladder may work to both increase eradication of local tumor as well as distant micrometastases through heightened immune surveillance. Due to the lack of a previous phase I trial establishing the safety of this combination (pembrolizumab, gemcitabine, and radiation therapy (RT)), an initial safety lead-in cohort of 3 to 6 patients is enrolled for assessing dose-limiting toxicities. Similar to the Phase I 3+3 design, if there is no or only one patient in that cohort experiencing a dose-limiting toxicity, the trial continues to the Phase II part to enroll additional 48 patients for efficacy evaluation.
DelveInsight’s Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
The leading Bladder Cancer Companies working in the market include UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
Promising Bladder Cancer Therapies in the various stages of development include Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.

Stay informed about the cutting-edge advancements in Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Bladder Cancer Clinical Trials Assessment

Bladder cancer Emerging Drugs Profile

UGN-102: UroGen Pharma Ltd.

UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen’s proprietary RTGel® technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.

APL 1202 : Asieris Pharmaceuticals

APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.

Trilaciclib: G1 Therapeutics, Inc.

Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.

Catumaxomab: LintonPharm Co.,Ltd.

Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell–and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.

VAX 014: Vaxiion Therapeutics

VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion’s proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either α3β1 or α5β1 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.

Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ Bladder Cancer Unmet Needs

Bladder Cancer Companies

UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Bladder Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Bladder Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Bladder Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Bladder Cancer Pipeline Report

Coverage- Global
Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ Bladder Cancer Drugs and Companies

Table of Content

Introduction
Executive Summary
Bladder Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
UGN-102: UroGen Pharma Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Trilaciclib: G1 Therapeutics, Inc.
Early Stage Products (Phase I)
VAX 014: Vaxiion Therapeutics
Inactive Products
Bladder Cancer Key Companies
Bladder Cancer Key Products
Bladder Cancer – Unmet Needs
Bladder Cancer – Market Drivers and Barriers
Bladder Cancer – Future Perspectives and Conclusion
Bladder Cancer Analyst Views
Bladder Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bladder Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

AIoT Platforms Market Size, Share, Growth Outlook, Driving Factors, Future Demand, Key Segmentation and Forecast to 2028

“IBM (US), Sharp Global (Japan), Google (US), AWS (US), Microsoft (US), Oracle (US), HPE (US), Cisco (US), Intel (US), Tencent Cloud (China), NXP (Netherlands), SAS (US), Hitachi (Japan), SAP (Germany), AxiomTek (Taiwan), Autoplant Systems India Pvt. Ltd. (India).”

AIoT Platforms Market by Offering (Solutions (Device Management, Application Management, Connectivity Management) and Services), Vertical (Manufacturing, Healthcare, Retail) and Region – Global Forecast to 2028.

The global AIoT platforms market is projected to expand from USD 5.0 billion in 2023 to USD 24.9 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 37.7% over the forecast period. This growth is anticipated to be driven by ongoing digital transformation across multiple industries and the widespread adoption of smart devices and IoT technology.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=4544896

By offering, solutions are estimated to account for the largest market share in 2023.

The demand for AIoT platforms solutions is increasing globally, due to the need for improved risk management capacity, optimization, decreased downtime, intelligent real-time monitoring of processes, and enhanced data management and analysis. Several leading platform providers, such as IBM, AWS, Google, Microsoft, and GE, offer IoT platforms integrated with AI capabilities, such as ML-based analytics. Most of the enterprises are deploying AIoT platforms because of their ability to churn insights quickly from bulk quantities of data generated from IoT devices.

Managed services are expected to register the fastest growth rate during the forecast period.

Managed services are considered crucial, as they are directly related to customer experience. These services help sustain their positions in the market. Nowadays, it has become difficult for companies to focus on core business processes and support various other functions, which, in turn, increases the significance of managed services. These services offer technical skills that are required to maintain and update software in the AIoT ecosystem. Integrated facility management, consultancy, round-the-clock help desk, finance, and accounts are some of the upcoming managed services required by operators. This segment is mainly driven by the increasing adoption of outsourced managed services in the AIoT market.

Asia Pacific is likely to emerge as the fastest-growing market during the forecast period

AIoT technology use is currently increasing in the Asia Pacific area. China, Japan, and India are the major countries contributing to the growth of the market in the region. A growing need for AIoT applications has been caused by the region’s vast population, strong adoption of mobile and internet technologies, and thriving manufacturing sector. In Asia-Pacific, industries like smart cities, healthcare, transportation, agriculture, and manufacturing are seeing a rise in adoption of AIoT. For instance, some Asian nations are launching projects to create smart cities that use AIoT technologies to enhance livability.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=4544896

Unique Features in the AIoT Platforms Market

AIoT platforms are uniquely designed to blend artificial intelligence (AI) with Internet of Things (IoT) capabilities, creating intelligent systems that can analyze vast amounts of data from connected devices in real time.

One of the standout features of AIoT platforms is the ability to process and analyze data in real time. This functionality is crucial for applications that require immediate insights, such as predictive maintenance, anomaly detection, and supply chain optimization. By analyzing data as it is generated, AIoT platforms empower organizations to make rapid, informed decisions and improve operational outcomes.

AIoT platforms often incorporate edge computing to perform data processing closer to the source of data generation, minimizing latency and reducing reliance on cloud resources. This feature is particularly beneficial for time-sensitive applications, like autonomous vehicles and industrial automation, where rapid response times are critical.

With the integration of AI, AIoT platforms can implement sophisticated security measures, such as anomaly detection, threat prediction, and automated responses to potential breaches. These platforms often include strong encryption protocols and access controls to protect sensitive data generated by IoT devices, addressing growing concerns around cybersecurity and privacy in connected environments.

AIoT platforms are built to scale, accommodating a growing number of connected devices and data sources across various industries. This scalability allows businesses to expand their AIoT deployments as needs evolve, whether in smart cities, industrial automation, healthcare, or retail.

Major Highlights of the AIoT Platforms Market

The AIoT platforms market is experiencing substantial growth, driven by increasing demand for intelligent and connected systems across industries. As organizations seek to improve efficiency and decision-making, AIoT platforms offer a powerful solution by integrating AI capabilities with IoT infrastructures.

AIoT platforms are at the core of digital transformation initiatives, enabling smart automation and improved data-driven decision-making. By automating processes and analyzing data in real time, AIoT platforms help organizations reduce operational costs and improve productivity.

A major highlight of the AIoT platforms market is the focus on real-time data processing and predictive analytics. AIoT solutions allow businesses to monitor operations continuously and predict potential issues before they occur, such as equipment malfunctions or supply chain disruptions.

With the proliferation of connected devices, cybersecurity has become a top priority in the AIoT platforms market. Platforms now include advanced security features, such as AI-driven threat detection and automated responses, to protect against cyber risks.

Edge computing has emerged as a crucial component of AIoT platforms, enabling faster data processing and reducing latency by bringing computation closer to where data is generated. This trend is driving the adoption of AIoT solutions in industries requiring real-time processing, such as autonomous vehicles, industrial automation, and healthcare.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=4544896

Top Companies in the AIoT Platforms Market

The major vendors covered in the AIoT platforms market include IBM (US), Sharp Global (Japan), Google (US), AWS (US), Microsoft (US), Oracle (US), HPE (US), Cisco (US), Intel (US), Tencent Cloud (China), NXP (Netherlands), SAS (US), Hitachi (Japan), SAP (Germany), AxiomTek (Taiwan), Autoplant Systems India Pvt. Ltd. (India), Williot (Israel), Cognosos (US), Relayr (US), Terminus Group (China), Semifive (South Korea), Uptake (Chicago), Falkonry (US), and Sightmachine (US).

IBM (US) is one of the leading vendors that provide AIoT platforms solutions. The company has a wide product portfolio for AIoT platforms and and related solutions. The R&D investments of the company are applied generally to all product areas, with specific areas of focus being identified regularly. The company’s recent areas of increased focus include smart infrstructure solutions, AI and hybrid cloud capalities along with IoT. IBM’s business offerings are focused on helping businesses modernize and transform their operations using innovative technology solutions. The company’s AI capabilities, including IBM Watson, are vital to this strategy, helping businesses integrate AI into their operations to improve efficiency and drive innovation.

Sharp Global (Japan) is a notable player in the AIoT (Artificial Intelligence of Things) platforms market, combining its expertise in AI and IoT to provide innovative solutions. Sharp Global’s AIoT platforms enable seamless integration of intelligent devices, real-time data analytics, and advanced automation. These solutions enhance operational efficiency, optimize resource utilization, and improve decision-making across various industries, positioning Sharp Global as a leader in the AIoT market.

Google (US) specializes in Internet-related services and products, which include online advertising technologies, cloud computing, software, and hardware. Its core products and platform include Android, Chrome, Gmail, Google Drive, Google Maps, Google Play, Search, and YouTube. Each product has over one billion active global users every month. Google’s product innovation has made its services widely used, making it one of the most recognized brands in the world. Google offers AIoT platforms designed to help businesses and developers build and manage connected devices at scale. Google Cloud IoT provides a suite of services and tools to connect, manage, and analyze data from IoT devices.

AxiomTek (Taiwan) is a key player in the AIoT (Artificial Intelligence of Things) platforms market, offering advanced solutions that integrate AI and IoT technologies. Their AIoT platforms provide robust capabilities for real-time data analytics, intelligent device management, and automation. These solutions help industries enhance operational efficiency, optimize processes, and drive innovation, making AxiomTek a prominent leader in the AIoT market.

SAP (Germany) is a major player in the AIoT (Artificial Intelligence of Things) platforms market, offering integrated solutions that combine AI and IoT technologies. Key offerings include the SAP Leonardo platform, which enables real-time data processing, advanced analytics, and machine learning capabilities. These solutions help businesses improve operational efficiency, enhance decision-making, and drive digital transformation, positioning SAP as a leader in the AIoT market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AIoT Platforms Market Size, Share, Growth Outlook, Driving Factors, Future Demand, Key Segmentation and Forecast to 2028

Asthma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Asthma Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Asthma Research. Learn more about our innovative pipeline today! @ Asthma Pipeline Outlook

Key Takeaways from the Asthma Pipeline Report

In October 2024:- Macleods Pharmaceuticals- A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (Distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients With Stable Mild Asthma
In October 2024:- Chiesi Farmaceutici S.p.A- A 12 Week, Randomized, Double-blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared to CHF 718 pMDI 800µg Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
In October 2024:- Regeneron Pharmaceuticals- The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA.
In October 2024:- Teva Branded Pharmaceutical- A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma. The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 35 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria.
In October 2024:- Sanofi- This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.
In October 2024:- Amgen- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma. The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
In October 2024:- AstraZeneca- A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma.
In October 2024:- Haisco Pharmaceutical Group Co., Ltd.- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma. This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma.
DelveInsight’s Asthma pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Asthma treatment.
The leading Asthma Companies such as GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.

Stay informed about the cutting-edge advancements in Asthma treatments. Download for updates and be a part of the revolution in care @ Asthma Clinical Trials Assessment

Asthma Emerging Drugs Profile

GSK3511294: GlaxoSmithKline

GSK’294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. In patients with severe eosinophilic asthma, targeted anti-IL-5 therapies are a well-established and effective treatment approach. GSK3511294 is currently being investigated in Phase III stage of Clinical trial evaluation for the treatment of Asthma.

TQC2731: Chia Tai Tianqing Pharmaceutical Group

TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

AZD4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

FB704A: Oneness Biotech Co., Ltd.

FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. FB704A (anti-IL-6 Ab) can reduce bronchial hyperresponsiveness as well as the Th1, Th2, and Th17 inflammatory responses of the respiratory tract, inhibit IL-6 classic- and trans-signaling pathways, and therefore have a chance of improving the symptoms of severe asthma (with high neutrophils) and severe mixed-granulocytic asthma. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

ARO-RAGE: Arrowhead Pharmaceuticals

ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases. It is currently being investigated in Phase I stage of Clinical trial evaluation for the treatment of Asthma.

Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs

Asthma Companies

GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Asthma Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Asthma treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Asthma Market Drivers and Barriers, and Future Perspectives

Scope of the Asthma Pipeline Report

Coverage- Global
Asthma Companies- GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Oneness Biotech Co., Ltd., Arrowhead Pharmaceuticals, Areteia Therapeutics, Jiangsu HengRui Medicine, SinoMab BioScience Ltd, Incyte Corporation, CSPC ZhongQi Pharmaceutical, Advagene Biopharma Co. Ltd., Beijing Kanova Biopharmaceutical, Inmunotek, Roche, Sanofi, ARS Pharmaceuticals, and others.
Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Asthma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Asthma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
GSK3511294: GlaxoSmithKline
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TQC2731: Chia Tai Tianqing Pharmaceutical Group
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ARO-RAGE: Arrowhead Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Asthma Key Companies
Asthma Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Asthma Analyst Views
Asthma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…

Triller Group Inc. (NASDAQ: ILLR) is making waves in the social media and AI sectors with new advancements, stirring up the stock market as investors rally behind the company’s innovative moves. With a new CEO and a strategic leadership transformation, Triller is positioning itself for an ambitious growth trajectory.

With short interest in Triller skyrocketing, the cost to borrow has hit 106%, and with shares in short supply, the market is witnessing an uptrend similar to the GameStop (NYSE: GME) short squeeze in 2021, which was famously amplified by “Roaring Kitty.” Triller’s rally is drawing comparisons as Alphabet Inc. (NASDAQ: GOOG), Reddit Inc. (NYSE: RDDT), and Triller Group Inc. (NASDAQ: ILLR) show significant movement this week. Triller is now seen as a high-potential stock in the social media space, aligned with industry players like Alphabet/Google and Reddit and Triller AI poised to disrupt and transform the social media landscape.

Triller Group Strengthens Leadership with New CEO and Board Member

In a move signaling long-term growth, Triller has appointed Kevin McGurn as CEO, effective November 2024. McGurn, formerly with Hulu, Vevo, and T-Mobile, has a track record of driving ad revenue and expanding digital media footprints. His vision positions Triller as a leader in vertical video, music, and sports, optimized for mobile and connected TV. Additionally, James McCann, founder of 1-800-Flowers.com, joins Triller’s board as Chairman of the Nominations Committee, bringing governance expertise from Willis Towers Watson, Scott’s Miracle-Gro, and IGT.

See Other Stocks with Rising “Short Interest” in a similar pattern to Triller Group Inc. (NASDAQ: ILLR)

Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Peraso Inc. (NASDAQ: PRSO)
Tharimmune Inc. (NASDAQ: THAR)

These stocks are also attracting significant attention as short interest grows, drawing increased interest from both retail and institutional investors for their market potential.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…